MTOR and non-small cell lung carcinoma: Although Osimertinib resistance is more complex, much evidence has implied that activation of the PI3K/AKT/mTOR pathway is required for Osimertinib resistance in NSCLC (EGFR Bypass Activation Pathway) [44].